Skip to main content
. 2008 Apr 29;98(9):1525–1532. doi: 10.1038/sj.bjc.6604318

Figure 3.

Figure 3

Influence of anhydrotetracycline (ATc) and trastuzumab on membrane localisation of ERBB2. (A) Untreated NIH3T3-HER2 tumour; (B) positive control; (C) NIH3T3-HER2 tumour 3 h after injection of trastuzumab; (D) NIH3T3-HER2 tumour treated for 7 days with trastuzumab; (E) NIH3T3-HER2 tumour 3 h after injection of ATc; (F) NIH3T3-HER2 tumour treated for 7 days with ATc.